Sirtex Medical delivered the first genuine breakthrough in the treatment of liver cancer in a generation, back in the early 2000’s. Use has now expanded to just over a thousand hospitals globally, generating A$264mil in revenue and A$54mil in NPAT in FY16. Yet the company is still only tackling a small fraction of the potential market. Stuart Roberts of NDF Research estimates that the company still has only 2% market penetration, but that three clinical trials are due to report in the next twelve months, positive results from which would allow Sirtex to address far more of the remaining 98% of the market. The stock has been consolidating for most of the year, though there may be significant blue sky ahead. In this video, Stuart Roberts explains why Sirtex is one he will be watching: